BCI Company Comparison Matrix

Brain-Computer Interface Company Comparison Matrix

Overview

Brain-Computer Interface Company Comparison Matrix

Overview

This page provides a comprehensive comparison of leading Brain-Computer Interface (BCI) companies, covering their technology, FDA status, and primary applications["@grand2024"]. This includes both emerging BCI companies developing novel neural interfaces and established neuromodulation companies with FDA-approved deep brain stimulation (DBS) and responsive neurostimulation (RNS) systems.

Company Comparison Matrix

Invasive BCI Companies (Emerging)

| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Funding |
|---|---|---|---|---|---|---|---|
| Neuralink | ~1,024 | High | <20ms | Invasive (64-thread implant) | FDA Breakthrough Device (human trials) | Quadriplegia, blindness | ~$280M |
| Blackrock Neurotech | 1,000+ | Very High | <10ms | Invasive (Utah Array) | FDA approved (clinical use) | Neuroscience research, ALS | ~$30M |
| Paradromics | 65,000+ | Very High | <20ms | Invasive (Utah Array) | FDA Breakthrough Device | Communication for paralyzed patients | ~$60M |
| BrainGate | 96-128 | Very High | <20ms | Invasive (Utah Array) | Clinical trials | Quadriplegia, ALS | Research funded |

Established Neuromodulation (DBS/RNS)

| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Patients Treated |
|---|---|---|---|---|---|---|---|
| Medtronic | 4-8 | High | <50ms | Invasive (DBS implant) | FDA Approved (1997) | Parkinson's, essential tremor | 150,000+ |
| Abbott Laboratories | 8 | High | <50ms | Invasive (Infinity DBS) | FDA Approved (2016) | [Parkinson's disease](/diseases/parkinsons-disease) | 20,000+ |
| Boston Scientific | 8 | High | <50ms | Invasive (Vercise DBS) | FDA Approved (2017) | Parkinson's disease | 10,000+ |
| NeuroPace | 4-8 | Medium | <100ms | Invasive (RNS implant) | FDA Approved (2013) | Epilepsy | 5,000+ |

Minimally Invasive BCI Companies

| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Funding |
|---|---|---|---|---|---|---|---|
| Synchron | 16 | Medium | <100ms | Minimally invasive (stentrode) | FDA [IDE](/entities/insulin-degrading-enzyme) (Investigational Device Exemption) approved | Paralysis, ALS | ~$60M |
| Precision Neuroscience | 1,024+ | High | <20ms | Minimally invasive (Layer 7) | FDA Breakthrough Device | Memory, vision restoration | ~$70M |
| Science Corp | 1,024+ | High | <20ms | Minimally invasive (optic nerve) | Pre-clinical | Vision restoration | Seed |
| Motif Neurotech | 64-256 | Medium | <50ms | Minimally invasive (piston implant) | Pre-clinical | Memory augmentation | ~$10M |
| Forest Neurotech | 100+ | High | <20ms | Minimally invasive (thin-film) | Pre-clinical | Neural recording | ~$5M |

Non-Invasive BCI Companies

| Company | Electrode Count | Bandwidth | Latency | Invasiveness | FDA Status | Primary Application | Funding |
|---|---|---|---|---|---|---|---|
| Kernel | 1,000+ | High | <50ms | Non-invasive (helmets) | R&D | Neuroscience research | ~$10M |
| MindMaze | 64+ | Medium-High | <30ms | Non-invasive (VR+EEG) | FDA cleared (rehabilitation) | Stroke rehab, VR | ~$185M |
| g.tec | 64-256 | High | <20ms | Non-invasive (EEG caps) | FDA cleared | Neuroscience research, BCI | ~$15M |
| EMOTIV | 32-64 | Medium | <50ms | Non-invasive (EEG headset) | FDA cleared | Consumer BCI, research | ~$20M |
| Bitbrain | 32-64 | Medium | <50ms | Non-invasive (EEG wearables) | FDA cleared | Health monitoring, attention | ~$20M |
| Neurable | 8-32 | Low-Medium | <100ms | Non-invasive (headset) | Product development | Gaming, productivity | ~$12M |
| Cognixion | 64+ | Medium | <50ms | Non-invasive (EEG+AR) | FDA Breakthrough Device | Communication for AAC | ~$21M |
| BrainCo | 16-64 | Medium | <50ms | Non-invasive (EEG headband) | FDA cleared | Focus training, HFOs | ~$20M |
| CTRL-Labs | 8-16 | Medium | <50ms | Non-invasive (wrist EMG) | Acquired (Meta 2019) | AR/VR control | $500M-$1B |
| NextMind | 8-16 | Low-Medium | <100ms | Non-invasive (EEG headband) | Acquired (Snap 2023) | Visual attention, gaming | Seed |

Detailed Analysis

Pipeline

Technology Comparison by Category

Emerging Invasive BCI (high bandwidth, novel implants):

• Neuralink: 64 threads with 1,024 electrodes each, wireless transmission, fully implantable[@neuralink2024]
• Blackrock Neurotech: Utah Array platform with established clinical history[@willett2021]
• Paradromics: High-density 65,000+ electrode array, first patient implanted in 2024[@paradromics2024]
• BrainGate: Academic-clinical consortium, 96-128 electrode arrays, decades of clinical data

• Medtronic: Pioneer in DBS since 1997, Activa PC/RC neurostimulators, 150,000+ patients treated worldwide, established safety profile
• Abbott Laboratories: Infinity DBS system acquired via St. Jude Medical merger (2016), smallest IPG, directional leads, 20,000+ patients
• Boston Scientific: Vercise DBS systems (FDA approved 2017/2020), AI-powered Neural Navigator programming, INTREPID trial data
• NeuroPace: Responsive Neurostimulation (RNS) system for epilepsy, FDA approved 2013, first closed-loop epilepsy device, 5,000+ implants

• Synchron: Stentrode placed via jugular vein, motor imagery control[@oxley2021]
• Precision Neuroscience: Layer 7 cortical interface, micro-electrode array
• Science Corp: Blindsight system targeting optic nerve for vision restoration
• Motif Neurotech: Piston-style implant for memory augmentation
• Forest Neurotech: Thin-film arrays for chronic recording

• Kernel: Flow and Flux helmets using fNIRS/MEG technologies
• MindMaze: VR-based neurorehabilitation platform with EEG
• g.tec: High-end research EEG systems with g.NAmp amplifiers
• EMOTIV: Consumer-grade EPOC headsets for BCI applications
• Bitbrain: Wearable EEG for health monitoring and cognitive assessment
• Neurable: Direct neural control for gaming and productivity
• Cognixion: OneSpeak AAC system combining EEG with AR interface
• BrainCo: Focus headband and BrainCo OS platform
• CTRL-Labs: Wrist-worn EMG interface (acquired by Meta), decodes muscle signals before physical movement
• NextMind: EEG-based visual attention decoding (acquired by Snap), real-time cognitive state analysis

FDA Status Summary

| Status | Companies |
|---|---|
| FDA Approved (clinical use) | Blackrock Neurotech, Medtronic, Abbott, Boston Scientific, NeuroPace |
| FDA Cleared | MindMaze, g.tec, EMOTIV, Bitbrain, BrainCo |
| Human Trials | Neuralink, Synchron, Paradromics, BrainGate |
| FDA Breakthrough Device | Precision Neuroscience, Cognixion |
| Pre-clinical | Science Corp, Motif Neurotech, Forest Neurotech |
| R&D | Kernel, Neurable |
| Acquired (Active Development) | CTRL-Labs (Meta), NextMind (Snap) |

Clinical Evidence Summary

Invasive BCI Clinical Outcomes

Neuralink PRIME Study (NCT05126784)

• First human implant (January 2025): Patient demonstrated ability to control computer cursor, play chess, and interact with software using neural signals[@neuralink2025]
• Signal quality: 1,024 electrodes recording from motor [cortex](/brain-regions/cortex)
• Performance: High-accuracy motor intent decoding (>90% accuracy for cursor movement)
• Safety: No serious adverse events reported in initial cohort

• Utah Array clinical use: Established safety profile with >15 years of clinical data
• Published outcomes: Willett et al. (2021) demonstrated high-performance handwriting communication at 90+ characters per minute[@willett2021]
• Patients treated: Multiple clinical centers worldwide using Blackrock systems

• Completed enrollment: 6 patients with severe paralysis
• Primary endpoint: Motor function improvement and device safety
• Results: Stentrode successfully enabled motor imagery control of external devices[@oxley2021]
• FDA approval expected: 2026

• First human implant: 2024
• Device: Connexus Direct Data Interface with 65,000+ electrodes
• Target: High-bandwidth communication for paralyzed patients[@paradromics2024]

Established Neuromodulation Clinical Evidence

Medtronic DBS for Parkinson's Disease

• Long-term outcomes: STING-AD and EARLYSTIM trials demonstrate significant motor symptom improvement (40-60% reduction in OFF medication time)[@deuschl2006]
• Patients treated: >150,000 worldwide since 1997
• Quality of life: PDQ-39 improvement of 20-30% in treated patients[@deuschl2006]

• Double-blind randomized controlled trial
• Results: 46% improvement in motor scores vs. sham
• FDA approval: 2020 for Vercise DBS system[@boston2020]

• Clinical evidence: THUNDER trial demonstrated comparable outcomes to Medtronic
• Advantage: Directional leads reduce side effects by 50%[@kuhn2018]

• SANTE Trial (NCT00572195): 29% reduction in seizure frequency at 2 years, 50%+ reduction at 5 years[@bergey2015]
• Patients: >5,000 implants since FDA approval in 2013
• First closed-loop neurostimulation system[@neuropace2013]

Non-Invasive BCI Clinical Evidence

MindMaze Stroke Rehabilitation

• FDA Cleared: 2021 for neurorehabilitation
• Clinical trials: Multiple RCTs demonstrating improved motor recovery vs. standard therapy
• Outcomes: 20-30% improvement in Fugl-Meyer Assessment scores[@mindmaze2021]

• Clinical use: Research and clinical applications for locked-in syndrome
• Performance: P300 speller achieving 70-90% accuracy in spelling tasks

• Target: AAC communication for ALS and cerebral palsy
• Clinical trials: Ongoing for communication accuracy and speed

Clinical Evidence Quality Assessment

| Technology | Evidence Level | Key Studies | Outcomes |
|------------|---------------|--------------|----------|
| Medtronic DBS | Level I (RCT) | STING-AD, EARLYSTIST | 40-60% motor improvement |
| Boston Scientific DBS | Level I (RCT) | INTREPID | 46% motor improvement |
| NeuroPace RNS | Level I (RCT) | SANTE | 29-50% seizure reduction |
| Blackrock Utah Array | Level II-III | Multiple cohort studies | High-bandwidth decoding |
| Synchron Stentrode | Level II | COMMAND Trial | Motor imagery control |
| Neuralink | Level II | PRIME Study | High-accuracy cursor control |
| MindMaze | Level I (RCT) | Multiple trials | 20-30% motor improvement |
| BCI Spelling | Level II-III | Multiple studies | 70-90% accuracy |

Market Landscape

The BCI market is rapidly evolving with significant investment flowing into both invasive and non-invasive approaches. The market includes two distinct segments: emerging BCI companies developing novel neural interfaces for paralyzed patients, and established neuromodulation companies with FDA-approved DBS and RNS systems treating movement disorders and epilepsy.

Key Trends (2024-2025)

Cross-References

Emerging Invasive BCI

• Neuralink
• Blackrock Neurotech
• Paradromics
• BrainGate

Established Neuromodulation

• Medtronic
• Abbott Laboratories
• Boston Scientific
• NeuroPace

Minimally Invasive BCI

• Synchron
• Precision Neuroscience
• Science Corp
• Motif Neurotech
• Forest Neurotech

Non-Invasive BCI

• Kernel
• MindMaze
• g.tec
• EMOTIV
• Bitbrain
• Neurable
• Cognixion
• BrainCo
• CTRL-Labs
• NextMind
• [Cell Types Overview](/companies/overview)
• [Disease Overview](/companies/overview)

External Links

Emerging BCI

• Neuralink Website
• Synchron Website
• Blackrock Neurotech Website
• Paradromics Website
• Precision Neuroscience Website

Established Neuromodulation

• Medtronic DBS Website
• Abbott Neuromodulation Website
• Boston Scientific DBS Website
• NeuroPace RNS Website

Non-Invasive BCI

• Kernel Website
• Science Corp Website
• MindMaze Website
• g.tec Website
• EMOTIV Website
• Bitbrain Website
• Neurable Website
• Cognixion Website
• BrainCo Website

Applications in Neurodegenerative Diseases

BCI technologies are being developed and applied to various neurodegenerative conditions:

Amyotrophic Lateral Sclerosis (ALS)

• Neuralink: Targeting communication restoration for ALS patients through neural decoding of intended speech[@neuralink2024]
• Blackrock Neurotech: Utah Array systems used in ALS research for motor function restoration
• Synchron: Stentrode for communication in late-stage ALS patients[@oxley2021]
• BrainGate: Clinical trials include ALS patients for cursor control and communication[@braingate]

Parkinson's Disease

• Medtronic: FDA-approved DBS systems for Parkinson's motor symptoms (tremor, rigidity)[@medtronic2024]
• Abbott Laboratories: Infinity DBS system for Parkinson's disease treatment[@abbott2016]
• Boston Scientific: Vercise DBS with AI navigation for Parkinson's[@boston2020]

Epilepsy

• NeuroPace: RNS system — first FDA-approved closed-loop responsive neurostimulation for epilepsy[@neuropace2013]

Stroke Rehabilitation

• MindMaze: FDA-cleared VR rehabilitation BCI for stroke motor recovery[@mindmaze2021]
• OpenBCI: Research platforms for stroke rehabilitation BCI studies

Alzheimer's Disease and Memory Disorders

• Precision Neuroscience: Layer 7 cortical interface targeting memory restoration
• Motif Neurotech: Minimally invasive memory augmentation implant
• See also: Memory Prosthetic BCI for [Alzheimer's Disease](/diseases/alzheimers-disease)

2026 Device Updates and Clinical Trials

Neuralink Updates (2025-2026)

• N1 Chip: First human implant completed in 2025, demonstrating successful signal transmission from 1,024 electrodes
• PRIME Study: Human trials expanded to 10+ patients with quadriplegia, showing high-bandwidth motor intent decoding
• Telepathy: Consumer version announced for 2026, targeting mobility assistance
• Blindsight: FDA breakthrough device designation for visual cortex bypass, first prosthetic vision trials

Synchron Updates (2025-2026)

• COMMAND Trial: Completed enrollment, FDA approval expected 2026
• Stentrode Gen 2: Increased electrode count (16→32), improved signal quality
• Switch Device: New wireless control hub for motor switching

Blackrock Neurotech (2025-2026)

• MoveAgain BCI: FDA approval for neural interface system (2025)
• Utah Array Gen 3: New flexible array with increased longevity
• Cerebus Interface: Updated for wireless operation

Paradromics (2025-2026)

• Connexus Direct Data Interface: Entering human trials in 2026
• 65,000 electrode array: Highest channel count in development

Precision Neuroscience (2025-2026)

• Layer 7 Cortical Interface: FDA breakthrough device, human trials planned 2026
• 1,024 channel system: High-resolution mapping capability

References

Pathway Diagram

The following diagram shows the key molecular relationships involving BCI Company Comparison Matrix discovered through SciDEX knowledge graph analysis: